pharmaphorum
MARCH 16, 2021
million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies. The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time it takes to develop a drug candidate.
XTalks
AUGUST 8, 2024
Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy. They combine the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs to destroy cancer cells, without harming healthy tissue. For the antibody component, the specificity of tumor cells is paramount. “We
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
FEBRUARY 25, 2021
All told, 80% of the patients have now been treated with this less frequent treatment regimen for more than two years with the efficacy maintained, according to the partners, and no new patients have developed antibodies against the drug – a perennial concern with ERT and something that can reduce its effectiveness.
pharmaphorum
JANUARY 29, 2021
While tanezumab is an antibody and has to be delivered by subcutaneous injection, AK1780 is orally bioavailable. Along with tanezumab and AK1780, Lilly is also developing LY3016859, an antibody that blocks two different cellular targets (TGF alpha and epiregulin), in phase 2 for chronic pain.
Roots Analysis
MAY 21, 2024
In fact, it has been observed that around 40% of the pharmaceutical drugs approved by regulatory organizations exhibit poor bioavailability / solubility. Further, every year, poor bioavailability is one of the main causes of drug failure in obtaining approval authorization.
Delveinsight
AUGUST 25, 2020
The drug, Spartalizumab, is an experimental monoclonal antibody designed as immunotherapy to target the human programmed death-1 (PD-1) receptor. The drug is directly delivered to lungs via inhalation to achieve high local exposures, and address the concerns of low oral bioavailability linked to niclosamide. .
The Pharma Data
APRIL 7, 2023
This is a fine balance to achieve – if the compounds are too large, they may not pass through the cell membrane, and their bioavailability would be affected; if they are too small, they would not retain high specificity to the target protein (or proteins).
Expert insights. Personalized for you.
101 
Let's personalize your content